A potentially very lucrative arrangement with a peer doesn't necessarily make the company a buy. A big name in COVID-19 care Much of Novavax's name recognition comes from the thick of the COVID-19 pandemic, as the company developed one of only four vaccines for the disease that got emergency use authorization from the U.S. Food and Drug Administration. That's a tough act to follow, and Novavax hasn't yet proven it can build out a long-term, sustainable business. So, like Smith, I can envision more downside ...

Novavax shares have soared and plummeted in recent years. The company also announced positive clinical-trial data for its combined flu/coronavirus vaccine candidate and aims to launch a phase 3 trial in the second half of this year. Finally, Novavax holds a key asset, one that could brighten the earnings picture. I'm talking about the company's Matrix-M adjuvant technology -- an ingredient that boosts the immune system's response to a particular vaccine. Novavax uses Matrix-M in its vaccine and candidates, ...

Moderate success regarding a new licensing deal with Sanofi could make the troubled vaccine stock a top performer. Shares of the struggling vaccine developer Novavax (NVAX 47.63%) bounded 98.7% higher on Friday, May 10. The market was responding to terrific news from Sanofi (NASDAQ: SNY), a global pharmaceutical giant that wants to market Novavax's COVID-19 and influenza vaccines. The recent Novavax stock rally continued after the weekend and investors are right to wonder if it has more fuel to climb higher ...

| Event: | Investor Meetings | | --- | --- | | Date: | Wednesday, May 15, 2024 | GAITHERSBURG, Md., May 13, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in the BofA Securities 2024 Health Care Conference. Conference Details: | Fireside Chat | | | --- | --- | | Date: | Wednesday, May 15, 2024 | | Time: | 3:00 – 3:30 p.m. Pacific Daylight Time (PDT) | | Location: | Encore Hotel in Las Vegas ...

However, Novavax had been unable to enjoy these benefits as it had a delayed product launch thanks to some manufacturing issues which led to delayed regulatory filings and a delayed approval. In the last year, management had uncertainties about generating revenues from COVID-19 vaccine sales and raised concerns about its ability to continue as a 'going concern.' With the backing of a pharma bigwig like Sanofi, Novavax expects to increase the market share and presence of its COVID vaccine to a larger audienc ...

Shares of Novavax jumped as much as 50% on Monday as Wall Street cheered the company's new multibillion- dollar deal with French drugmaker Sanofi that sparked a dramatic turnaround for the struggling vaccine maker. Novavax's stock almost doubled on Friday after it announced the licensing agreement with Sanofi. Novavax on Friday said the deal allows the company to remove its "going concern" warning, which it first issued in February 2023 due to major doubts about its ability to stay afloat. "It really does h ...

The 2020 U.S. equity crash and subsequent rebound was the perfect storm for a unique event called the "Meme" stock craze. After the panic lows of March 2020, stocks bottomed, and the government started to pump liquidity into the market and everyday Americans with stimulus checks. With many people working remotely, confined to their homes, and with more money in their pockets, Americans started trading in the stock market. By 2021, a message board called "Wallstreetbets" gained a cult-like following on the s ...

Luis Alvarez Novavax (NASDAQ:NVAX) has just announced mixed Q1 2024 earnings with a beat on EPS and a miss on revenue. NVAX surged by around 175% in premarket trading as investors applauded that their net loss narrowed by around 50% year-over-year to $148M, thanks to a 16% increase in revenue. In addition, investors were relieved to see the removal of the company’s going concern notice in the 10-Q, which was one of the geneses of the ticker’s relentless sell-off. However, I believe the primary cause of ...

Novavax, Inc. (NASDAQ:NVAX) Q1 2024 Earnings Conference Call May 10, 2024 8:30 AM ET Company Participants Erika Schultz - Senior Director of Investor Relations John Jacobs - President and Chief Executive Officer James Kelly - Chief Financial Officer and Treasurer John Trizzino - President and Chief Operating Officer Filip Dubovsky - President of Research and Development Conference Call Participants Roger Song - Jefferies Eric Joseph - JPMorgan Mayank Mamtani - B. Riley Securities Brendan Smith - TD Cowen Ve ...

A cloud of doubt hanging over the company just gave way to some sunshine.Shares of Novavax (NVAX 96.20%) are up 12% as of midday Friday following the release of the drugmaker's first-quarter results. It's not the report, however, driving the bulk of today's oversize gain -- it's the announcement made in conjunction with it.The company is partnering with fellow pharmaceutical company Sanofi (SNY 0.90%) to market Novavax's COVID vaccine. The deal also opens the door to the development of a flu vaccine based o ...